Apples and oranges. You are first of all talking about a device, not a “drug” with almost no SAEs (i.e. Vascepa), and secondly a device that if manufactured deficiently would result in extreme morbidity.
As stated, FDA applies a risk-based approach to CGMP compliance surveillance.
News 
Market Data 
Discover 
